Join        Login             Stock Quote

Two diabetes drugs better than one

Monday, April 30, 2012 11:12 PM

AURORA, Colo., April 30 (UPI) -- Metformin and rosiglitazone, used together, were more effective in treating youth with recent-onset type 2 diabetes than metformin alone, U.S. researchers say.

Dr. Philip Zeitler, study chairman and a pediatric endocrinologist at Children's Hospital Colorado, in Aurora, said the study found metformin therapy alone was not an effective treatment for many of the youth affected by the illness.

The Treatment Options for type 2 Diabetes in Adolescents and Youth study is the first major comparative effectiveness trial for the treatment of type 2 diabetes in young people. The study tested how well and for how long each of three treatment approaches controlled blood glucose levels in subjects ages 10-17 with type 2 diabetes.

Participants were randomly assigned to one of three treatment groups -- metformin alone, metformin and rosiglitazone together, and metformin plus intensive lifestyle changes aimed at helping participants lose weight and increase physical activity.

The study, published in the New England Journal of Medicine, found treatment with metformin alone was inadequate for maintaining acceptable, long-term, blood glucose control in 51.7 percent of youth during an average follow-up of 46 months.

The failure rate was 38.6 percent in the metformin and rosiglitazone group, a 25.3 percent reduction in the rate for metformin alone. In the metformin-plus-lifestyle group the failure rate was 46.6 percent.

(Source: UPI )
(Source: Quotemedia)


Related Stories

  • No Stories Found


Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.